Riskpilot← Back to searchSign inGet full accessBiomapas Nordic AB
ABActiveOrg 5591661797Kungsbro Strand 29Research and experimental development on natural sciences and engineering · NACE 7210Est. 20181-4 employees
Revenue 2024
SEK 70K
-86% vs 2023
EBITDA margin
5.7%
-98% vs 2023
Equity ratio
94.8%
Financial strength
Net profit 2024
SEK -1K
-101% vs 2023
| Revenue | SEK 70K | -86% |
| EBITDA | SEK 4K | -98% |
| Net profit | SEK -1K | -101% |
| Total assets | SEK 268K | -29% |
| Equity | SEK 254K | +0% |
| Employees | — | — |
Legal name
Biomapas Nordic AB
Org number
5591661797
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17 juli 2018
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget bedriver verksamhet med tidiga till sena faser av kliniska prövningar, regulatoriska frågor och farmako- materielövervakningslösningar för livsvetenskapindustrin.
Address
Kungsbro Strand 29
Email
info@biomapas.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 761 | 2 266 | 516 | 70 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −35 | −33 | 146 | 192 | 4 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −35 | −33 | 146 | 192 | 4 |
| Net financials | — | — | — | — | −4 |
| Profit before tax | −35 | −33 | 145 | 193 | 0 |
| Tax | −0 | −0 | −23 | −41 | −1 |
| Net profit | −35 | −33 | 122 | 152 | −1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 48 | 149 | 393 | 380 | 268 |
| Equity | 14 | −20 | 103 | 255 | 254 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 35 | 168 | 290 | 125 | 15 |
| Total debt | 35 | 168 | 290 | 125 | 15 |
EBITDA margin
5.7%
This company
15.8%
Market median
-64% vs market
20202024
Equity ratio
94.8%
This company
38.2%
Market median
+148% vs market
20202024
Return on equity
-0.4%
This company
18.4%
Market median
-102% vs market
20202024
Net profit margin
-1.4%
This company
8.1%
Market median
-117% vs market
20202024
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20202024
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TS Authorized Recipient of Service | Authorized Recipient of Service | 2020 |
| Former (1) | ||
JO Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biomapas Nordic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Taave Sööt Vahermägi | Authorized Recipient of Service | 0 companies |
| Jan Ola Jeppsson | Chief Executive Officer | 0 companies |
| Risteski,Filip | Deputy Board Member | 0 companies |
| Edgaras Kabecius | Deputy Board Member | 0 companies |
| Audrius Sveikata | Board of Directors | 0 companies |